Renaissance Technologies’s Ovid Therapeutics OVID Stock Holding History

Renaissance Technologies’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.45M	Sell	1,104,300 -380,178	-26%	-$680K	﹤0.01%	1788
2025 Q4	$2.42M	Sell	1,484,478 -533,546	-26%	-$822K	﹤0.01%	1746
2025 Q3	$2.62M	Sell	2,018,024 -77,285	-4%	-$67K	﹤0.01%	1900
2025 Q2	$691K	Buy	2,095,309 +1,071,509	+105%	+$323K	﹤0.01%	2678
2025 Q1	$319K	Buy	1,023,800 +916,100	+851%	+$563K	﹤0.01%	2911
2024 Q4	$101K	Buy	107,700 +63,200	+142%	+$70.7K	﹤0.01%	3285
2024 Q3	$52.5K	Sell	44,500 -96,700	-68%	-$101K	﹤0.01%	3337
2024 Q2	$109K	Sell	141,200 -15,600	-10%	-$43.4K	﹤0.01%	3168
2024 Q1	$478K	Buy	156,800 +105,600	+206%	+$353K	﹤0.01%	2884
2023 Q4	$165K	Sell	51,200 -29,600	-37%	-$101K	﹤0.01%	3191
2023 Q3	$310K	Sell	80,800 -33,900	-30%	-$122K	﹤0.01%	2918
2023 Q2	$376K	Sell	114,700 -5,900	-5%	-$20K	﹤0.01%	3022
2023 Q1	$311K	Buy	120,600 +800	+0.7%	+$1.9K	﹤0.01%	3103
2022 Q4	$223K	Buy	119,800 +1,000	+0.8%	+$1.7K	﹤0.01%	3368
2022 Q3	$219K	Sell	118,800 -5,000	-4%	-$10.5K	﹤0.01%	3350
2022 Q2	$266K	Buy	123,800 +39,000	+46%	+$94.2K	﹤0.01%	3521
2022 Q1	$266K	Buy	84,800 +26,200	+45%	+$82.4K	﹤0.01%	3525
2021 Q4	$188K	Buy	58,600 +24,100	+70%	+$82.6K	﹤0.01%	3531
2021 Q3	$116K	Buy	+34,500	New	+$126K	﹤0.01%	3296
2021 Q1	–	Sell	-710,507	Closed	-$1.64M	–	3601
2020 Q4	$1.64M	Buy	+710,507	New	+$3.31M	﹤0.01%	2244
2020 Q3	–	Sell	-624,109	Closed	-$4.6M	–	3595
2020 Q2	$4.6M	Sell	624,109 -228,734	-27%	-$1.07M	﹤0.01%	1695
2020 Q1	$2.54M	Sell	852,843 -231,866	-21%	-$781K	﹤0.01%	1936
2019 Q4	$4.5M	Buy	1,084,709 +497,984	+85%	+$1.57M	﹤0.01%	1914
2019 Q3	$1.9M	Buy	586,725 +115,116	+24%	+$262K	﹤0.01%	2307
2019 Q2	$872K	Buy	471,609 +108,392	+30%	+$194K	﹤0.01%	2743
2019 Q1	$643K	Buy	363,217 +308,117	+559%	+$771K	﹤0.01%	2848
2018 Q4	$133K	Buy	+55,100	New	+$251K	﹤0.01%	3196

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies's OVID Position: Q1 2026 in Review

Renaissance Technologies reduced its Ovid Therapeutics (OVID) stake by 26% in Q1 2026, selling an estimated $680K and leaving 1,104,300 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1788.

Renaissance Technologies first reported a position in OVID in Q4 2018 and has held it in 27 quarters since. The position peaked at $4.6M in Q2 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Renaissance Technologies held 1,104,300 shares of Ovid Therapeutics worth $2.45M as of Q1 2026.
Renaissance Technologies sold 380,178 Ovid Therapeutics shares in Q1 2026, an estimated $680K.
Ovid Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1788 holding.
Renaissance Technologies first reported a position in Ovid Therapeutics in Q4 2018 and has held it in 27 quarters since.
Renaissance Technologies's Ovid Therapeutics position peaked at $4.6M in Q2 2020.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.